I definitely agree that MSB is going to do its own marketing and I sure damn hope so. It has been stated very clearly that MSB is going to do the marketing and distribution of aGvHD without a partner so they HAVE to establish a global marketing and sales force, nothing new there.
So while these jobs are obviously meant for aGvHD, you cant draw any conclusions about partnerships for the other indications for which MSB actually wants a distribution partner.
I still think that approval of aGvHD will be a trigger for partnerships for other indications and thats smart because each de-risking step increased the value of the potential deals. I dont necessarily expect a deal for either CLBP or CHF before FDA approval of aGvHD. Anything that comes early will be a pleasant surprise though
MSB Trading - 2019, page-1039
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.005(0.32%) |
Mkt cap ! $1.798B | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.52 | $6.446M | 4.092M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 62215 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 14678 | 2 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |